Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 1/2 1

Status

Completed 2Suspended 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Neoplasms 2012Carcinoma, Non-Small-Cell Lung 1228Breast Neoplasms 1215Leukemia, Myeloid, Acute 967Neoplasm Metastasis 902Melanoma 778Colorectal Neoplasms 752Multiple Myeloma 725Lymphoma 725Ovarian Neoplasms 675Pancreatic Neoplasms 665Lymphoma, Non-Hodgkin 659Prostatic Neoplasms 657Recurrence 637Precursor Cell Lymphoblastic Leukemia-Lymphoma 585Lung Neoplasms 560Leukemia, Lymphocytic, Chronic, B-Cell 555Glioblastoma 527Leukemia 486Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 419Brain Neoplasms 415Squamous Cell Carcinoma of Head and Neck 389Stomach Neoplasms 387Carcinoma, Renal Cell 385Myelodysplastic Syndromes 382Carcinoma, Hepatocellular 368Advanced Solid Tumors 357Lymphoma, Mantle-Cell 345Glioma 343

Interventions

radium Ra 223 dichloride 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Castrate-Resistant Prostate Cancer × Clear all
NCT04053062 2024-01-05

LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer

Bioray Laboratories

Phase 1 Suspended
12 enrolled
Genitourinary

Castrate-Resistant Prostate Cancer

NCT04768608 2023-07-17

PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer

Zhejiang University

Phase 1 Completed
3 enrolled
Genitourinary

Castrate-Resistant Prostate Cancer

NCT02814669 2019-09-24

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Hoffmann-La Roche

Phase 1 Completed
45 enrolled
Genitourinary

Castrate-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡